Allergy Therapeutics Share Discussion Threads

[audigger] 30/11/2015 07:37

Another step forward.

[jimmyloser] 25/11/2015 19:27

ALLERGY THERA.

25 Nov 2015 18:06:58

Allergy Therapeutics RNS Number : 9885G

Allergy Therapeutics PLC 25 November 2015


Grant of Options under Long Term Incentive Plan


Allergy Therapeutics plc confirms that certain performance conditions attaching to provisional awards ("Awards") made pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three years ended 30 June 2015, details of which were announced on 19 December 2012, have been met. Consequently, Allergy Therapeutics has today granted certain of its directors nil cost options ("Options") over the Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in replacement for the Awards made under the LTIP as follows:

Director

Number of Ordinary Shares over which Options granted

Total number of Ordinary Shares over which Options granted

Total remaining number of Ordinary Shares provisionally awarded under LTIPs


Manuel Llobet,

Chief Executive Officer

624,024

624,024

2,595,000


Ian Postlethwaite,

Finance Director

312,012

475,512

1,297,500




The Options have been granted in accordance with the LTIP rules and can be exercisable at nil cost between 25 December 2015 and 25 December 2018.



For further information:




Allergy Therapeutics

[phone]


Manuel Llobet, Chief Executive Officer





Ian Postlethwaite, Finance Director












Panmure Gordon

[phone]


Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance





Tom Salvesen, Corporate Broking

[treeshake] 24/11/2015 11:27

and the start of the upward cycle commences

[celeritas] 23/11/2015 14:32

Just about top up time.

[little minx] 18/11/2015 15:51

Yes it is and will grow further in months ahead

[kidknocked] 18/11/2015 15:37

Looking good here little minx...

[qackers] 18/11/2015 14:20

New interview out.

Allergy Therapeutics medical chief on Polyvac Peanut potential
Share

18 Nov 2015

Matthias Kramer, international medical director at Allergy Therapeutics (OTCMKTS:AGYTF) discusses Polyvac Peanut – the company’s new peanut allergy product which the firm says gives it exposure to an US$8bn a year market.

He spoke to Proactive after Allergy outlined plans to raise up to £12mln via a share placing.

As well as strengthening its balance sheet and accelerating growth with existing vaccine products, the firm is looking to create new products aimed at tackling food allergies and Polyvac Peanut is the start.

[jimmyloser] 18/11/2015 07:11

Well guys, they do not make statements any bolder than this. It seems that Manuel has well and truly lit the blue touch paper so we should all stand back and wait for the fireworks that they have promised us. I expect a slow burn with the occasional whizz bang before the spectacular starts! impo/dyor

"Allergy Therapeutics is raising up to £12 million through the issue of up to 41,005,500 new ordinary shares - approximately 7.5% of the company's existing ordinary share capital - at no less than 28p apiece.

In the financial year ended 30 June, the company's sales measured in constant currency grew by 11% over the prior period. As announced today, sales have continued to increase since the year-end, growing by 15%, including sales from Alerpharma, acquired in June 2015, in the first four months of the new financial year against the same period in 2014.

|It says the placing builds on the gathering trading momentum and the proceeds will enable the Board to capitalise on incremental organic and inorganic growth opportunities for the company and its subsidiaries.

The Company will use the clacing proceeds to invest in new product development with a view to achieving a step change in the size of its total addressable markets, strengthen its balance sheet and accelerate growth".

Chief executive Manuel Llobet said: "We have seen an increase of our revenue growth rate during the first four months of the year despite flat markets. We believe that this continuing increased demand for our products highlights the strong profile of our portfolio and, in particular, our short course aluminium free allergy vaccines driving double digit revenue growth in our European markets. In light of this continuing momentum in our business, we are seeking to raise up to £12 million to accelerate execution of our growth strategy.

The Placing proceeds will help us develop a presence in related areas such as food and perennial allergies such as house dust mite which, ultimately, will enable us to achieve a step-change in the size of the Group's total addressable market."

[celeritas] 17/11/2015 13:09

All filled nice and early, didn't have to wait until the end of the day for the rns.

[jimmyloser] 17/11/2015 12:54

As mentioned earlier - OVERSUBSCRIBED.


Manuel Llobet, Chief Executive Officer, stated:

"We are delighted with the result of this oversubscribed fundraising and would like to take the opportunity to welcome new investors in the Company as well as thank our existing investors for their continued support. We look forward to putting the proceeds of the Placing to use in the business, with a view to generating significant additional value for our shareholders".

[jimmyloser] 17/11/2015 10:42

I agree. I also impo expect the book is already over subscribed !
AGM tomorrow and Manuel doing his selling bit on Monday!

[celeritas] 17/11/2015 10:24

The company are grabbing the bull by the horns and seizing the opportunity. I'm betting institutions have already sounded them out and wanted stock, makes it easier for them this way. I expect whoever acquires stock in the book build will keep on building.
I'm hoping for a chance myself. AGY should be 3 times it's current price going by peers so I expect this will move pretty fast once the book build is out the way.

[audigger] 17/11/2015 10:10

Well my top- up wasn't timed so well as I didn't see a placement coming so soon. I'm in for the long term so have no issue with taking a hit short term especially as they are looking to enter yet another high value market. Also good to see the underlying business continues to grow in strength. I still think we'll be back around 35p at Xmas.....if not, I shall be adding more!

[jimmyloser] 17/11/2015 08:30

POSTED ON OCTOBER 28TH 2015

Thanks for this excellent post.

Am I alone in believing that the company and its advisors are now actively talking the price up? - another placing perhaps for another piece of that growth strategy.

[celeritas] 17/11/2015 08:16

New mkts and a placing.
I was only reading about the peanut allergy mkt last week wondering if agy would move to food..
This is a huge step change in ambition.

[jimmyloser] 17/11/2015 07:09

STRONG TRADING


17 November 2015





Allergy Therapeutics plc

("Allergy Therapeutics" or the 'Company")



Trading Update





Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today provides the following trading update covering the first four months of the 2016 financial year ("the Period").



European demand for Allergy Therapeutics' unique short course aluminium free allergy vaccines has continued to be strong since the year ended 30 June 2015. The Company's like-for-like sales measured in constant currency increased by 12% in the Period compared with the same period in 2014. Including the Alerpharma acquisition completed in June 2015, constant currency sales increased 15% over the Period. Growth was notably strong in Germany, Austria, Netherlands and Spain and the Company continued to increase its market share during the Period.



Given the results are traditionally strongly weighted towards the first half of the Company's financial year, the Board remains confident of strong results for the full year.



The Board also announces today that the Company has acquired the licence for Virus Like Particles ("VLP"), a new technology to be used in the treatment of peanut allergy, an $8bn p.a. addressable market globally. The Company intends to use the VLP licence in the development of Polyvac Peanut, a new injectable vaccine immunotherapy treatment for allergy sufferers, through to Phase I clinical trials. Polyvac Peanut represents the Company's first move into products for treatment of food allergies and, to demonstrate the extent of the market opportunity, in the US alone, there are approximately 3 million people with peanut allergy and 100 - 150 attributable deaths each year. This therefore represents a significant and strategically important new area for the Group.



The Company also continues to progress a number of other opportunities in existing and new areas of immunotherapy treatment, including its programme to clinically develop Pollinex Quattro Grass through to FDA approval and subsequent launch in the US, anticipated for 2019. The Board believes that a combination of the Company's strong product profile, positive sales momentum coupled with an ongoing disciplined investment in research and development will continue to win market share and accelerate growth in the current year and beyond.



In light of the gathering momentum across all areas of the business, the Board will today also announce a placing to raise up to £12 million for the Company, to enable the Group to capitalise further on the incremental organic and inorganic growth opportunities available.


SECOND RNS





17 November 2015



Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")



Proposed placing to raise up to £12 million



Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces a placing of up to 41,005,500 new ordinary shares of 0.1 pence each in the capital of the Company ("New Shares"), representing approximately 7.5% of the Company's existing ordinary share capital, to raise up to £12 million.



Highlights




·

Placing of up to 41,005,500 New Shares in the Company ("Placing"), representing approximately 7.5% of the Company's existing ordinary share capital, at a price of no less than 28 pence per New Share ("Placing Price") to raise up to approximately £12 million before expenses.


·

In the financial year ended 30 June 2015, the Company's sales measured in constant currency grew by 11% over the prior period. As announced today, sales have continued to increase since the year-end, growing by 15%, including sales from Alerpharma, acquired in June 2015, in the first four months of the new financial year against the same period in 2014. The Placing builds on the gathering trading momentum and the proceeds will enable the Board to capitalise on incremental organic and inorganic growth opportunities for the Company and its subsidiaries (the "Group").


·

The Company will use the Placing proceeds to invest in new product development with a view to achieving a step change in the size of its total addressable markets, strengthen its balance sheet and accelerate growth.




The Placing is being conducted through an accelerated bookbuilding process (the "Bookbuild") which will be commenced immediately in accordance with the terms and conditions set out in Appendix I to this announcement.



Panmure Gordon (UK) Limited ("Panmure Gordon") is acting as Financial Adviser, Nominated Adviser and Corporate Broker in respect of the Placing.



Manuel Llobet, Chief Executive Officer, stated:

"We have seen an increase of our revenue growth rate during the first four months of the year despite flat markets. We believe that this continuing increased demand for our products highlights the strong profile of our portfolio and, in particular, our short course aluminium free allergy vaccines driving double digit revenue growth in our European markets. In light of this continuing momentum in our business, we are seeking to raise up to £12 million to accelerate execution of our growth strategy. The Placing proceeds will help us develop a presence in related areas such as food and perennial allergies such as house dust mite which, ultimately, will enable us to achieve a step-change in the size of the Group's total addressable market."

[jimmyloser] 13/11/2015 19:16

Au Digger,
I too have topped up this week and also like you it was the highest price that I have paid. I feel very lucky to have come on board many moons ago.
These today now look credible to me at least and with the AGM next week and the main man on the charm offensive on the 23rd then that smacks of an outfit feeling at ease with the expectations that are being placed on it.

I am sure that all readers agree that any positive news now from the company in relation to the USA or of any of the myriad of potentially blockbusting new product lines that are opening up to them, should be received very favourably by the markets.

The last fund raising at 23p suddenly looks very cheap indeed.

I am personally happy with the three year plus timelines and I am in for the longer haul.

impo/dyor

[audigger] 13/11/2015 18:55

Topped up today, highest price I've paid for these. I'm all for a thread devoid of lunatics.....still plenty of them posting on other threads

[audigger] 12/11/2015 20:46

Good note from hardman, thanks Cel. The cash burn analysis is interesting and looks a little over stated given that the us trials are covered by the 20 million. I guess sales and marketing in to the us business opportunity will be a key challenge. One of the most scientific research notes I've seen, immunology 101!

[audigger] 12/11/2015 20:46

Good note from hardman, thanks Cel. The cash burn analysis is interesting and looks a little over stated given that the us trials are covered by the 20 million. I guess sales and marketing in to the us business opportunity will be a key challenge. One of the most scientific research notes I've seen, immunology 101!

[treeshake] 12/11/2015 20:09

CEL - off topic somewhat but do you feel advfn is getting quieter these days ? Never seen the platform so quiet and I've been around for years - twitter seems very good for this game as its self regulated as opposed to the rubbish over here these days

[jimmyloser] 12/11/2015 16:13

AGM next week - will we get a statement?

[celeritas] 12/11/2015 15:55

Commercialisation of Pollinex Quattro in the US represents a huge opportunity and
has the potential to transform the company. This is reflected in our risk-adjusted DCF valuation which suggests a value of 93p per share. This is supported by a peer comparative valuation which shows a considerable mis-match in the value of AGY versus its immediate peers. This is surprising given that the current market leaders do not offer the same growth opportunities, in contrast to the direct comparator Circassia), which does not have any market experience compared to AGY.

[celeritas] 12/11/2015 15:52

Nice one TS, here's a recent bit of reading


I've been in opti since the 30s as I thought is was undervalued against peers.
AGY is much the same, needs to close that gap.

[treeshake] 12/11/2015 13:22

AD - can't see any reason that it shouldnt